Natera
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
Barclays Initiates Coverage of Guardant Health, Exact Sciences, Natera With Overweight Rating
The investment firm cited large, unpenetrated markets for liquid biopsy in residual disease detection, monitoring, and screening.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Jan 2, 2025
360Dx Top 30 Rebounds in 2024, Rises 4 Percent
Nov 12, 2024
Natera Q3 Revenues Grow 64 Percent
Aug 1, 2024
360Dx Top 30 Jumps 11 Percent in July
Jun 5, 2024